From The ASCO Post
Outcomes are typically grim for patients with recurrent glioblastoma multiforme. At the 2019 Annual Scientific Meeting of the American Association of Neurological Surgeons (AANS), three early-stage studies hinted at ways that standard treatments might be made more effective.
Metronomic Dosing of Temozolomide May Enhance Efficacy of Checkpoint Inhibition
The efficacy of temozolomide, when combined with checkpoint inhibition, may be enhanced by metronomic dosing, according to a study from University of Florida researchers and reported by Maryam Rahman, MD, MS, of the Brain Tumor Immunotherapy Program.